Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 84
- Registration Number
- NCT03654768
- Locations
- ๐บ๐ธ
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
๐บ๐ธAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
๐บ๐ธAlaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
- Conditions
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT03578367
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
๐บ๐ธGeorgia Regents University, Augusta, Georgia, United States
๐ฌ๐งNovartis Investigative Site, Oxford, United Kingdom
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT03516279
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธGood Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States
๐บ๐ธBethesda North Hospital, Cincinnati, Ohio, United States
Efficacy and Safety of Nilotinib in CML-CP
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT03332511
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02973711
- Locations
- ๐บ๐ธ
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธWake Forest University Health Sciences, Winston-Salem, North Carolina, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- ๐ณ๐ฑ
Meander medisch centrum, Amersfoort, Netherlands
๐ณ๐ฑNetherlands Cancer Institute, Amsterdam, Netherlands
๐ณ๐ฑAmsterdam UMC, locatie AMC, Amsterdam, Netherlands
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- European LeukemiaNet
- Target Recruit Count
- 75
- Registration Number
- NCT02917720
- Locations
- ๐ฉ๐ช
Klinikum Chemnitz, Chemnitz, Germany
๐ฉ๐ชOnkologische Schwerpunktpraxis, Esslingen, Germany
๐ฉ๐ชSchwerpunktpraxis Onkologie, Heilbronn, Germany
Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Institut Bergoniรฉ
- Registration Number
- NCT02774512
- Locations
- ๐ซ๐ท
Institut Bergoniรฉ, Bordeaux, France
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2650
- Registration Number
- NCT02733445
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Emory University
- Target Recruit Count
- 7
- Registration Number
- NCT02709083
- Locations
- ๐บ๐ธ
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.